Willow Biosciences Inc. (CANSF)
OTCMKTS
· Delayed Price · Currency is USD
0.0050
+0.0005 (11.11%)
Apr 25, 2025, 4:00 PM EDT
Willow Biosciences Revenue
In the year 2024, Willow Biosciences had annual revenue of 4.66M CAD with 297.78% growth. Willow Biosciences had revenue of 1.88M in the quarter ending December 31, 2024, with 2,014.61% growth.
Revenue
4.66M CAD
Revenue Growth
+297.78%
P/S Ratio
0.16
Revenue / Employee
245.37K CAD
Employees
19
Market Cap
522.60K USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.66M | 3.49M | 297.78% |
Dec 31, 2023 | 1.17M | 351.00K | 42.75% |
Dec 31, 2022 | 821.00K | 688.00K | 517.29% |
Dec 31, 2021 | 133.00K | 123.00K | 1,230.00% |
Dec 31, 2020 | 10.00K | 5.00K | 100.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Willow Biosciences News
- 4 weeks ago - WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY - PRNewsWire
- 3 months ago - WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS - PRNewsWire
- 5 months ago - WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PRNewsWire
- 6 months ago - WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO - PRNewsWire
- 7 months ago - WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT - PRNewsWire
- 8 months ago - WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC. - PRNewsWire
- 9 months ago - WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PRNewsWire
- 9 months ago - WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY - PRNewsWire